Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12

Inflammatory Bowel Diseases

Volumn 19, Issue 6, 2013, Pages 1130-1138

  Däbritz, Jan ^a,b,c   Langhorst, Jost ^d   Lügering, Andreas ^e   Heidemann, Jan ^f   Mohr, Miriam ^d   Wittkowski, Helmut ^a   Krummenerl, Thomas ^g   Foell, Dirk ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d KLINIKEN ESSEN MITTE   (Germany)

^e MVZ   (Germany)

^f OWL University   (Germany)

^g Gastroenterology Clinic   (Germany)

Author keywords

Calprotectin; Crohn's disease; Fecal marker; Serum; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; S100A12 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NEUTROPHIL; PANCOLITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; INTESTINES; MALE; MIDDLE AGED; NEUTROPHILS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; ROC CURVE; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84879200332     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318280b1cd     Document Type: Article

References (36)

1. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894-1899.
2. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut. 2009;58:859-868.
3. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nature Med. 2007;13:1042-1049.
4. Foell D, Ichida F, Vogl T, et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet. 2003;361:1270-1272.
5. Wittkowski H, Sturrock A, van Zoelen MA, et al. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med. 2007;35:1369-1375.
6. Foell D, Wittkowski H, Ren Z, et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol. 2008;216:183-192.
7. Foell D, Ren Z, Wittkowski H, et al. Phagocyte-specific S100 proteins are activators of pattern recognition receptors and released during active inflammatory bowel disease [abstract]. Gastroenterology. 2008; 134:A517.
8. Foell D, Wittkowski H, Luken A, et al. The mediator S100A12 is critically involved in early inflammatory events of inflammatory bowel disease [abstract]. Gastroenterology. 2009;136:A254.
9. de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm Bowel Dis. 2006;12:566-572.
10. Leach ST, Yang Z, Messina I, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007; 42:1321-1331.
11. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847-853.
12. Manolakis AC, Kapsoritakis AN, Georgoulias P, et al. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol. 2010;10:118.
13. Däbritz J, Langhorst J, Luegering A, et al. Multicentre follow-up study of phagocyte-derived S100A12 as a surrogate marker of intestinal inflammation in inflammatory bowel disease [abstract]. Gastroenterology. 2012;142:S781.
14. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007;56:1706-1713.
15. Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359-366.
16. Manolakis AC, Kapsoritakis AN, Tiaka EK, et al. Calprotectin, calgranu-lin C, and other members of the s100 protein family in inflammatory bowel disease. Dig Dis Sci. 2011;56:1601-1611.
17. Judd TA, Day AS, Lemberg DA, et al. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011;26: 1493-1499.
18. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
19. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
20. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
21. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.
22. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423-432.
23. Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207-1212.
24. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
25. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54:364-368.
26. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007-2014.
27. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669-673.
28. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lacto-ferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190-1198.
29. Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005;11:1085-1091.
30. Gerasimidis K, Nikolaou CK, Edwards CA, et al. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol. 2011;45:234-239.
31. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal cal-protectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis. 2010;4:144-152.
32. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22:340-345.
33. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lacto-ferrin can identify postoperative recurrence in Crohn's disease. Br J Surg. 2009;96:663-674.
34. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-169.
35. de Suray N, Salleron J, Vernier-Massouill G, et al. Close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn's disease in remission after Infliximab withdrawal. a sub-analysis of the Stori study [abstract]. Gastroenterology. 2012;142:S149.
36. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after inflix-imab therapy is stopped. Gastroenterology. 2012;142:63-70 e65; quiz e31.